Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 0.44 |
| ▸ | HTR2A | P28223 | 7/20 | 0.44 |
| ▸ | HTR2B | P41595 | 7/20 | 0.44 |
| ▸ | HTR1A | P08908 | 6/20 | 0.44 |
| ▸ | HTR1D | P28221 | 5/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | PNMT | P11086 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.35 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.35 |
| ▸ | ITGAL | P20701 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30289569 | 1.00 | HTR2C (0.44) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL17841440 | 0.89 | MTNR1B (0.43) | MTNR1AMTNR1BPNMTITGB2ICAM1 | |
| SCHEMBL25374616 | 0.88 | HTR2C (0.39) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL6950651 | 0.83 | HTR2C (0.47) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL8463358 | 0.82 | MTNR1A (0.41) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL21872018 | 0.82 | MTNR1A (0.47) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL20669648 | 0.82 | MTNR1A (0.41) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL28218012 | 0.82 | MTNR1A (0.41) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL6682400 | 0.82 | MTNR1A (0.44) | HTR2CHTR2AHTR2BHTR1AHTR1D | |
| SCHEMBL27500349 | 0.79 | MTNR1A (0.42) | HTR2CHTR2AHTR2BHTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112004816-B | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2024-01-05 | — | — | CN | disclosed |
| WO-2023146987-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2023-05-04 | — | — | US | disclosed |
| WO-2023049723-A1 | PRC2 INHIBITORS FOR USE IN TREATING BLOOD DISORDERS | ORIC PHARMACEUTICALS, INC. (US) | 2023-03-30 | — | — | WO | disclosed |
| CN-108430972-B | Alpha, beta-unsaturated amide compound | 协和麒麟株式会社 | 2022-12-27 | — | — | CN | disclosed |
| US-11447471-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-09-20 | — | — | US | disclosed |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. | 2022-07-07 | — | — | US | disclosed |
| US-11332455-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2022-05-17 | — | — | US | disclosed |
| CN-114269748-A | Imidazo [1,2-c ] pyrimidine derivatives as PRC2 inhibitors for the treatment of cancer | 米拉蒂医疗股份有限公司 | 2022-04-01 | — | — | CN | disclosed |
| US-20210032252-A1 | PRC2 Inhibitors | Mirati Therapeutics, Inc. | 2021-02-04 | — | — | US | disclosed |
| WO-2020247475-A1 | IMIDAZO[1,2-C]PYRIMIDINE DERIVATIVES AS PRC2 INHIBITORS FOR TREATING CANCER | Mirati Therapeutics, Inc. (US) | 2020-12-10 | — | — | WO | disclosed |
| CN-112004816-A | PRC2 inhibitors | 米拉蒂医疗股份有限公司 | 2020-11-27 | — | — | CN | disclosed |
| WO-2020219448-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-10-29 | — | — | WO | disclosed |
| US-10787428-B2 | α,β-unsaturated amide compound | KYOWA KIRIN CO., LTD. (JP) | 2020-09-29 | — | — | US | disclosed |
| EP-3712129-A1 | ALPHA, BETA-UNSATURATED AMIDE COMPOUND | Kyowa Kirin Co., Ltd. (JP) | 2020-09-23 | — | — | EP | disclosed |
| CN-110770211-A | α unsaturated amide compound | 协和麒麟株式会社 | 2020-02-07 | — | — | CN | disclosed |
| WO-2019152419-A1 | PRC2 INHIBITORS | MIRATI THERAPEUTICS, INC (US) | 2019-08-08 | — | — | WO | disclosed |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2019-01-10 | — | — | US | disclosed |
| EP-3401309-A1 | a, ß UNSATURATED AMIDE COMPOUND | Kyowa Hakko Kirin Co., Ltd. (JP) | 2018-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447471-B2 | α,β-unsaturated amide compound | NR1H2, RXRA, RXRB | HTR2C 2266/4885HTR2A 1736/4885HTR2B 1351/4885 |
| US-10787428-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | HTR2C 1776/4885HTR2A 1319/4885HTR2B 1137/4885 |
| US-20220213097-A1 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS | BMI1, EZH2, SUZ12 | HTR2C 3677/4885HTR2A 3881/4885HTR2B 4009/4885 |
| US-20230137025-A1 | SUBSTITUTED IMIDAZO[1,2-c]PYRIMIDINES AS PRC2 INHIBITORS | EZH2, BMI1, SUZ12 | HTR2C 2505/4885HTR2A 3454/4885HTR2B 3883/4885 |
| US-11332455-B2 | α,β-unsaturated amide compound | NR1H2, NCOA1, NR0B1 | HTR2C 1776/4885HTR2A 1319/4885HTR2B 1137/4885 |
| US-20190010136-A1 | ALPHA,BETA-UNSATURATED AMIDE COMPOUND | NR1H2, NR1H3, NCOA1 | HTR2C 1907/4885HTR2A 1342/4885HTR2B 1109/4885 |
| US-20210032252-A1 | PRC2 Inhibitors | EZH2, BMI1, SUZ12 | HTR2C 3924/4885HTR2A 3992/4885HTR2B 4393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.